Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Nicholas J Burstow, Zameer Mohamed, Asmaa I Gomaa, Mark W Sonderup, Nicola A Cook, Imam Waked, C Wendy Spearman & Simon D Taylor-Robinson. (2017) Hepatitis C treatment: where are we now?. International Journal of General Medicine 10, pages 39-52.
Read now
Read now
Articles from other publishers (22)
Victória Riquena Grosche, Leandro Peixoto Ferreira Souza, Giulia Magalhães Ferreira, Marco Guevara-Vega, Tamara Carvalho, Romério Rodrigues dos Santos Silva, Karla Lilian Rodrigues Batista, Rodrigo Paolo Flores Abuna, João Santana Silva, Marília de Freitas Calmon, Paula Rahal, Luis Cláudio Nascimento da Silva, Bruno Silva Andrade, Claudener Souza Teixeira, Robinson Sabino-Silva & Ana Carolina Gomes Jardim. (2023) Mannose-Binding Lectins as Potent Antivirals against SARS-CoV-2. Viruses 15:9, pages 1886.
Crossref
Crossref
Wei Zhang, Lili Lin, Wanjin Fu, Dandan Bao, Qian Zhang, Yueyue Liu, Liang Zheng & Wei Hu. (2023) Pharmacokinetics, Safety, and Bioequivalence of 2 Lopinavir/Ritonavir (200/50 mg) Tablets in Healthy Chinese Volunteers: Effect of Food on Absorption. Clinical Pharmacology in Drug Development 12:6, pages 602-610.
Crossref
Crossref
Madeline Denison, Justin J. Ahrens, Marilyn N. Dunbar, Habon Warmahaye, Aliza Majeed, Claudia Turro, Thomas A. Kocarek, Irina F. Sevrioukova & Jeremy J. Kodanko. (2023) Dynamic Ir(III) Photosensors for the Major Human Drug-Metabolizing Enzyme Cytochrome P450 3A4. Inorganic Chemistry 62:7, pages 3305-3320.
Crossref
Crossref
Madeline Denison, Sean J. Steinke, Aliza Majeed, Claudia Turro, Thomas A. Kocarek, Irina F. Sevrioukova & Jeremy J. Kodanko. (2022) Ir(III)-Based Agents for Monitoring the Cytochrome P450 3A4 Active Site Occupancy. Inorganic Chemistry 61:35, pages 13673-13677.
Crossref
Crossref
Eric R. Samuels & Irina F. Sevrioukova. (2022) Interaction of CYP3A4 with Rationally Designed Ritonavir Analogues: Impact of Steric Constraints Imposed on the Heme-Ligating Group and the End-Pyridine Attachment. International Journal of Molecular Sciences 23:13, pages 7291.
Crossref
Crossref
Shi Cheng, Marcel M. van Gaalen, Mathias Bähr, Enrique Garea-Rodriguez & Sebastian Kügler. (2021) Optimized pharmacological control over the AAV-Gene-Switch vector for regulable gene therapy. Molecular Therapy - Methods & Clinical Development 23, pages 1-10.
Crossref
Crossref
Zequan Zhou, Suohui Zhang, Guozhong Yang & Yunhua Gao. (2021) Enhanced delivery efficiency and sustained release of biopharmaceuticals by complexation-based gel encapsulated coated microneedles: rhIFNα-1b example. Asian Journal of Pharmaceutical Sciences 16:5, pages 612-622.
Crossref
Crossref
Nicholas Toupin, Sean J. Steinke, Sandeep Nadella, Ao Li, Thomas N. RohrabaughJr.Jr., Eric R. Samuels, Claudia Turro, Irina F. Sevrioukova & Jeremy J. Kodanko. (2021) Photosensitive Ru(II) Complexes as Inhibitors of the Major Human Drug Metabolizing Enzyme CYP3A4. Journal of the American Chemical Society 143:24, pages 9191-9205.
Crossref
Crossref
Marit AC Vermunt, Andries M Bergman, Eric van der Putten & Jos H Beijnen. (2021) The intravenous to oral switch of taxanes: strategies and current clinical developments. Future Oncology 17:11, pages 1379-1399.
Crossref
Crossref
Bhavesh D. Kevadiya, Jatin Machhi, Jonathan Herskovitz, Maxim D. Oleynikov, Wilson R. Blomberg, Neha Bajwa, Dhruvkumar Soni, Srijanee Das, Mahmudul Hasan, Milankumar Patel, Ahmed M. Senan, Santhi Gorantla, JoEllyn McMillan, Benson Edagwa, Robert Eisenberg, Channabasavaiah B. Gurumurthy, St Patrick M. Reid, Chamindie Punyadeera, Linda Chang & Howard E. Gendelman. (2021) Pharmacotherapeutics of SARS-CoV-2 Infections. Journal of Neuroimmune Pharmacology 16:1, pages 12-37.
Crossref
Crossref
Eric R. Samuels & Irina F. Sevrioukova. (2021) Rational Design of CYP3A4 Inhibitors: A One-Atom Linker Elongation in Ritonavir-Like Compounds Leads to a Marked Improvement in the Binding Strength. International Journal of Molecular Sciences 22:2, pages 852.
Crossref
Crossref
Eric R. Samuels & Irina F. Sevrioukova. (2020) An increase in side-group hydrophobicity largely improves the potency of ritonavir-like inhibitors of CYP3A4. Bioorganic & Medicinal Chemistry 28:6, pages 115349.
Crossref
Crossref
Matti K. Itkonen, Aleksi Tornio, Outi Lapatto‐Reiniluoto, Mikko Neuvonen, Pertti J. Neuvonen, Mikko Niemi & Janne T. Backman. (2018) Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel. Clinical Pharmacology & Therapeutics 105:1, pages 219-228.
Crossref
Crossref
Lina Ibrahim Alnajjar. (2018) Review of the Novel Agents for Hepatitis C Infection in the Emergency Department. Current Emergency and Hospital Medicine Reports 6:4, pages 174-181.
Crossref
Crossref
Eric Lawitz, Mohamed Bidair, Thomas Marbury, Christopher T. Jones, Avantika Barve, Baldur Magnusson, David T. Barkan, Ursula Bodendorf, Kathryn Bracken, Erica Canino, Darlene Chen, Kristina Dabovic, Tycho Heimbach, Marjorie Ison, Catherine L. Jones, Steven J. Kovacs, Jay P. Lakshman, Bin Li, Prakash Raman, Rachael Steiner-Swiat, Sanjeev Thohan, Kelly A. Wong, Weidong Zhong & Richard A. Colvin. (2018) The Safety and Antiviral Activity of BZF961 with or without Ritonavir in Patients Infected with Hepatitis C Virus: A Randomized, Multicenter Trial. Clinical Therapeutics 40:9, pages 1567-1581.e4.
Crossref
Crossref
Daniel J. Ellenberger, Dave A. Miller, Sandra U. Kucera & Robert O. WilliamsIIIIII. (2018) Generation of a Weakly Acidic Amorphous Solid Dispersion of the Weak Base Ritonavir with Equivalent In Vitro and In Vivo Performance to Norvir Tablet. AAPS PharmSciTech 19:5, pages 1985-1997.
Crossref
Crossref
Eric R. Samuels & Irina Sevrioukova. (2017) Inhibition of Human CYP3A4 by Rationally Designed Ritonavir-Like Compounds: Impact and Interplay of the Side Group Functionalities. Molecular Pharmaceutics 15:1, pages 279-288.
Crossref
Crossref
David M. Burger, Lindsey H. M. te Brake & Rob E. Aarnoutse. 2018. Drug Interactions in Infectious Diseases: Mechanisms and Models of Drug Interactions. Drug Interactions in Infectious Diseases: Mechanisms and Models of Drug Interactions
15
47
.
Anna Garbelli, Valentina Riva, Emmanuele Crespan & Giovanni Maga. (2017) How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?. Biochemical Journal 474:10, pages 1559-1577.
Crossref
Crossref
Douglas D. DeCarolis, Anders D. Westanmo, Yi-Chie Chen, Amanda L. Boese, Mary A. Walquist & Thomas S. Rector. (2016) Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin. Annals of Pharmacotherapy 50:11, pages 909-917.
Crossref
Crossref
Robert J. Fontana, Robert S. Brown, Ana Moreno‐Zamora, Martin Prieto, Shobha Joshi, Maria‐Carlota Londoño, Kerstin Herzer, Kristina R. Chacko, Rudolf E. Stauber, Viola Knop, Syed‐Mohammed Jafri, Lluís Castells, Peter Ferenci, Carlo Torti, Christine M. Durand, Laura Loiacono, Raffaella Lionetti, Ranjeeta Bahirwani, Ola Weiland, Abdullah Mubarak, Ahmed M. ElSharkawy, Bernhard Stadler, Marzia Montalbano, Christoph Berg, Adriano M. Pellicelli, Stephan Stenmark, Francis Vekeman, Raluca Ionescu‐Ittu, Bruno Emond & K. Rajender Reddy. (2016) Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transplantation 22:4, pages 446-458.
Crossref
Crossref
D. Banerjee & K. R. Reddy. (2016) Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Alimentary Pharmacology & Therapeutics 43:6, pages 674-696.
Crossref
Crossref